Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer.

[1]  N. Hanna,et al.  PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy , 2003 .

[2]  M. Ratain,et al.  Weekly, high‐dose paclitaxel in advanced lung carcinoma , 2003, Cancer.

[3]  S. Urien,et al.  Weekly administration of paclitaxel: theoretical and clinical basis. , 2002, Critical reviews in oncology/hematology.

[4]  V. Alberola,et al.  Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. , 2002, Critical reviews in oncology/hematology.

[5]  V. Carañana,et al.  Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. , 2002, Japanese journal of clinical oncology.

[6]  M. Socinski,et al.  Second‐line, low‐dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first‐line chemotherapy with carboplatin plus paclitaxel , 2002, Cancer.

[7]  G. Koumakis,et al.  Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. , 2002, Lung cancer.

[8]  Michael J Schell,et al.  Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[10]  R. Lilenbaum,et al.  Phase II trial of weekly docetaxel in second‐line therapy for nonsmall cell lung carcinoma , 2001, Cancer.

[11]  A. Chang,et al.  Weekly paclitaxel in advanced non-small cell lung cancer. , 2001, Seminars in oncology.

[12]  T. Hickish,et al.  Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Giaccone,et al.  Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Kris,et al.  Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens , 2000 .

[15]  J. Dancey,et al.  Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Socinski.  Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. , 1999, The oncologist.

[17]  G. Scagliotti,et al.  Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[20]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[21]  S Lippman,et al.  Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[23]  P. Ganz,et al.  Karnofsky performance status revisited: reliability, validity, and guidelines. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[25]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[26]  David E Morris,et al.  Chemotherapeutic management of stage IV non-small cell lung cancer. , 2003, Chest.

[27]  L. Norton,et al.  Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[29]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[30]  D. Cox.  Regression Models and Life-Tables , 1972 .